|
|
M. Giulia Cangi, Barry Cukor, Peggy Soung, Sabina Signoretti, Gilberto Moreira Jr., Moksha Ranashinge, Blake Cady, Michele Pagano, Massimo Loda
J Clin Invest. 2000;
106(6):753
doi:10.1172/JCI9174
Abstract |
Full text
| PDF
T
he phosphatase Cdc25A plays an important role in cell cycle regulation by removing inhibitory phosphates from tyrosine and threonine residues of cyclin-dependent kinases, and it has been shown to transform diploid murine fibroblasts in cooperation with activated Ras. Here we show that Cdc25A is overexpressed in primary breast tumors and that such overexpression is correlated with higher levels of cyclin-dependent kinase 2 (Cdk2) enzymatic activity in vivo. Furthermore, in the breast cancer cell line MCF-7, Cdc25A activity is necessary for both the activation of Cdk2 and the subsequent induction of S-phase entry. Finally, in a series of small (< 1 cm) breast carcinomas, overexpression of Cdc25A was found in 47% of patients and was associated with poor survival. These data suggest that overexpression of Cdc25A contributes to the biological behavior of primary breast tumors and that both Cdc25A and Cdk2 are suitable therapeutic targets in early-stage breast cancer.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
About CrossRef
| Title and authors |
Publication |
Year |
. |
3,3′-Diindolylmethane negatively regulates Cdc25A and induces a G2/M arrest by modulation of microRNA 21 in human breast cancer cells
Yucui Jin, Xianghong Zou, Xiaoling Feng |
Anti-Cancer Drugs |
2010 |
.
|
Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis
Derek M. Murphy, Patrick G. Buckley, Kenneth Bryan, Karen M. Watters, Jan Koster, Peter van Sluis, Jan Molenaar, Rogier Versteeg, Raymond L. Stallings |
Molec Carcinogen |
2010 |
.
|
Dual Mode of Regulation of Cell Division Cycle 25 A Protein by TRB3
Satoshi Sakai, Nobumichi Ohoka, Kikuo Onozaki, Masatoshi Kitagawa, Makoto Nakanishi, Hidetoshi Hayashi |
Pharm Bull |
2010 |
.
|
Sp1 coordinately regulatesde novolipogenesis and proliferation in cancer cells
Suying Lu, Michael C. Archer |
Int J Cancer |
2010 |
.
|
CDC 25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma
Isik Didem Karagoz, Mehmet Ozaslan, Beyhan Cengiz, Mehmet Emin Kalender, Ibrahim Halil Kilic, Serdar Oztuzcu, Bulent Gogebakan, Abdullah Tuncay Demiryurek |
Tumor Biol |
2010 |
.
|
Mice with the CHEK2*1100delC SNP are predisposed to cancer with a strong gender bias
E. M. Bahassi, S. B. Robbins, M. Yin, G. P. Boivin, R. Kuiper, H. van Steeg, P. J. Stambrook |
Proc Natl Acad Sci U S A |
2009 |
.
|
LGH00031, a novel ortho-quinonoid inhibitor of cell division cycle 25B, inhibits human cancer cells via ROS generation
Yu-bo Zhou, Xu Feng, Li-na Wang, Jun-qing Du, Yue-yang Zhou, Hai-ping Yu, Yi Zang, Jing-ya Li, Jia Li |
Acta Pharmacol Sinica |
2009 |
.
|
Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases
Shugeng Cao, Brian T. Murphy, Caleb Foster, John S. Lazo, David G.I. Kingston |
biorg med chem |
2009 |
.
|
Cell Cycle Regulation by Oncogenic Tyrosine Kinases in Myeloid Neoplasias: From Molecular Redox Mechanisms to Health Implications
Margret S. Rodrigues, Mamatha M. Reddy, Martin Sattler |
Antioxidants & Redox Signaling |
2008 |
.
|
Targeting PTPs with small molecule inhibitors in cancer treatment
Zhong-Xing Jiang, Zhong-Yin Zhang |
Cancer Metastasis Rev |
2008 |
.
|
Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer
David Frescas, Michele Pagano |
Nat Rev Neurosci |
2008 |
.
|
Discovery and characterization of a novel inhibitor of CDC25B, LGH000451
Xu FENG, Li-na WANG, Yue-yang ZHOU, Hai-ping YU, Qiang SHEN, Yi ZANG, Yu-bo ZHOU, Jing-ya LI, Hai-xia ZHANG, Jia LI |
Acta Pharmacol Sin |
2008 |
.
|
Constitutive overexpression of CDC25A in primary human mammary epithelial cells results in both defective DNA damage response and chromosomal breaks at fragile sites
Maria Giulia Cangi, Sara Piccinin, Lorenza Pecciarini, Anna Talarico, Elena Dal Cin, Stefano Grassi, Alessandra Grizzo, Roberta Maestro, Claudio Doglioni |
Int J Cancer |
2008 |
.
|
CDC25 phosphatases in cancer cells: key players? Good targets?
Rose Boutros, Valérie Lobjois, Bernard Ducommun |
Nat Rev Neurosci |
2007 |
.
|
Using expression profiling data to identify human microRNA targets
Jim C Huang, Tomas Babak, Timothy W Corson, Gordon Chua, Sofia Khan, Brenda L Gallie, Timothy R Hughes, Benjamin J Blencowe, Brendan J Frey, Quaid D Morris |
Nat Methods |
2007 |
.
|
Alkylating agents and cancer therapy
Ranju Ralhan, Jatinder Kaur |
eotp |
2007 |
.
|
Inhibiting transient protein–protein interactions: lessons from the Cdc25 protein tyrosine phosphatases
Johannes Rudolph |
Nat Rev Neurosci |
2007 |
.
|
Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases
Weigang Huang, Jingya Li, Wei Zhang, Yueyang Zhou, Chuanming Xie, Yu Luo, Yunfei Li, Jingli Wang, Jia Li, Wei Lu |
Biorg Med Chem Lett |
2006 |
.
|
p53 downregulates expression of the G1/S cell cycle phosphatase Cdc25A
K Rother, R Kirschner, K Sänger, L Böhlig, J Mössner, K Engeland |
Oncogenes |
2006 |
.
|
Modeling of Cdc25B Dual Specifity Protein Phosphatase Inhibitors: Docking of Ligands and Enzymatic Inhibition Mechanism
Antonio Lavecchia, Sandro Cosconati, Vittorio Limongelli, Ettore Novellino |
ChemMedChem |
2006 |
.
|
|
|
|